Lung cancer is the most commonly diagnosed cancer in China and the second in the United States, approximately 85% of which is non–small cell lung cancer (NSCLC).
1 The precise stratification of patients with NSCLC into groups according to survival outcomes represents a crucial step in treatment. The staging system in the 8th edition of the American Joint Committee on Cancer classifies patients based on tumor, node, and metastasis (TNM) staging.
2 However, the survival rate within the same stage cohort varies widely.
3-5 It has been found that other independent prognostic factors including age, sex, histology, and treatment choices could significantly contribute to individualized predictions of survival.
6